Dare Bioscience (DARE) Accounts Payables (2013 - 2026)
Dare Bioscience's (DARE) quarterly Accounts Payables came in at $1.2 million in Q4 2025, down 17.53% YoY from $1.5 million in Q4 2024, and down 34.92% on a QoQ basis from $1.8 million in Q3 2025.
Dare Bioscience (DARE) Accounts Payables (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Accounts Payables data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Accounts Payables fell 17.53% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 17.53% YoY) and the FY2025 annual result came in at $1.2 million, down 17.53% from the prior year.
- Accounts Payables eased to $1.2 million in Q4 2025, from $1.8 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $6.5 million in Q2 2023 to a low of $216043.0 in Q2 2021.
- A 5-year average of $2.3 million and a median of $1.9 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2021 — Accounts Payables sank 87.4% — and 2023, when it soared 487.05%.
- Tracing DARE's Accounts Payables over 5 years: stood at $2.1 million in 2021, then retreated by 3.57% to $2.0 million in 2022, then jumped by 66.94% to $3.4 million in 2023, then slumped by 57.0% to $1.5 million in 2024, then fell by 17.53% to $1.2 million in 2025.
- The last three Accounts Payables figures came in at $1.2 million (Q4 2025), $1.8 million (Q3 2025), and $1.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 35.57 Mn |
| 10 | Dare Bioscience | 12.35 Mn | -269,456.53 | -132,343.00 | 762,914.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 762,914.00 |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 1.76 Mn |
| Mar 31, 2025 | 1.88 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.91 Mn |
| Mar 31, 2024 | 4.04 Mn |
| Dec 31, 2023 | 3.39 Mn |
| Sep 30, 2023 | 4.99 Mn |
| Jun 30, 2023 | 6.54 Mn |
| Mar 31, 2023 | 2.70 Mn |
| Dec 31, 2022 | 2.03 Mn |
| Sep 30, 2022 | 3.48 Mn |
| Jun 30, 2022 | 1.11 Mn |
| Mar 31, 2022 | 2.83 Mn |
| Dec 31, 2021 | 2.10 Mn |
| Sep 30, 2021 | 605,732.00 |
| Jun 30, 2021 | 216,043.00 |